A utomatic detection and transvenous or subcutaneous defibrillation of malignant ventricular arrhythmias by implantable cardioverter defibrillators are vital for management of patients at high risk for sudden cardiac death. Guidelines and appropriate use criteria based on data from several clinical trials support prophylactic defibrillator implantation in patients with symptoms of heart failure and left ventricular ejection fraction ≤35%.
1,2 Yet, existing guidelines direct defibrillator implantation to a small subset of the overall population at risk for sudden death, and with an average annual appropriate shock rate of 5.1%, many patients that receive an implantable defibrillator never require appropriate therapies and are exposed to device-related risks. 3, 4 The recent DANISH trial (Defibrillator Implantation in Patients with Non-Ischemic Systolic Heart Failure) found no mortality benefit with prophylactic defibrillator implantation in patients with symptomatic heart failure and nonischemic cardiomyopathy. 5 Thus, additional data are necessary to refine patient selection among patients with nonischemic cardiomyopathy that currently meet defibrillator implantation criteria. At the same time, criteria to identify high risk of sudden cardiac death among patients that are currently excluded must evolve. As many as 80% of those who experience out-of-hospital cardiac arrests would not meet current criteria for primary prevention defibrillator implantation before the event. [6] [7] [8] [9] These patients, who generally have preserved or nearly preserved cardiac function, have lower mortality risks competing with sudden cardiac death and stand to derive significant benefit from defibrillator implantation. Currently used measures of sudden cardiac death risk, however, are based on cardiac function rather than identification of the substrate for malignant arrhythmia. The left ventricular ejection fraction is readily quantifiable by echocardiography and has been used as the primary stratification tool in all major trials, but it is highly dependent on loading conditions, and is only an effective predictor of sudden cardiac death in subgroups of patients with direct association between scar extent and cardiac function.
In this issue of Circulation, Halliday et al 10 report findings from a prospective registry of 399 patients with nonischemic cardiomyopathy and left ventricular ejection fraction ≥40% not meeting current guidelines for defibrillator implantation. All patients underwent baseline cardiovascular MRI and were followed for a prespecified composite end point of sudden death or successful resuscitation from ventricular arrhythmia. Over nearly 5 years of follow-up, patients with midmyocardial late gadolinium enhancement on baseline cardiovascular magnetic resonance were more likely to have sudden cardiac death or aborted sudden cardiac death in comparison with those without late gadolinium enhancement (17.8% versus 2.3%, P<0.001). After adjustment for age, New York Heart Association class of heart failure, and left ventricular ejection fraction, the presence of late gadolinium enhancement predicted actual (hazard ratio, 4.8; P=0.003) and aborted (hazard ratio, 35.9; P<0.001) sud-den cardiac death. Based on Cox proportional hazard model parameters derived from their data, the predicted 5-year risk of sudden cardiac death was substantially attenuated after accounting for the presence or absence of late gadolinium enhancement. In fact, the 5-year sudden cardiac death risk for an individual with a left ventricular ejection fraction of 45% would be 20% with late gadolinium enhancement, in contrast to 3% in the absence of late gadolinium enhancement. If the risk for the same individual were assessed based on left ventricular ejection fraction alone, the risk would be estimated at 8%. These results demonstrate a significant incremental value for late gadolinium enhancement assessment in this population over the use of left ventricular ejection fraction alone, and indicate the possibility of identifying a previously neglected subgroup of patients at especially high risk for sudden cardiac death.
Midmyocardial late gadolinium enhancement on cardiac magnetic resonance is not disease specific, but often represents focal replacement fibrosis in patients with nonischemic cardiomyopathy. The presence of midmyocardial late gadolinium enhancement is associated with inducibility of ventricular tachycardia at electrophysiology study 11 and reduced voltage on endocardial mapping. 12 Midmyocardial late gadolinium enhancement sites appear to represent scar and heterogeneous myocardial tissues necessary for functional block, slow conduction, and the perpetuation of reentrant ventricular arrhythmias. 13 In fact, on invasive mapping, critical ventricular tachycardia sites often correspond to regions with midmyocardial late gadolinium enhancement. 12 Notably, despite significant arrhythmogenic potential, the left ventricular ejection fraction may be relatively preserved in the setting of midmyocardial late gadolinium enhancement. Several studies have evaluated the role of cardiac magnetic resonance for risk stratification in nonischemic cardiomyopathy. The majority have been single-center studies with relatively small numbers of patients, but the experience is growing and the bulk of data supports an association between midmyocardial late gadolinium enhancement and sudden cardiac death. 14, 15 Halliday and colleagues' results are encouraging as we look toward the ongoing CMR GUIDE trial (Cardiovascular Magnetic Resonance Guided Management of Mild-Moderate Left Ventricular Systolic Dysfunction; NCT01918215), a prospective, multicenter randomized trial examining the role of primary prevention defibrillator implantation in patients with mild to moderate left ventricular systolic dysfunction and evidence of myocardial fibrosis. These prospective data will be useful to define the clinical utility and cost-effectiveness of magnetic resonance-based scar assessment for risk stratification in patients with left ventricular ejection fraction >35%. The findings may enhance guidelines to include more patients at high risk for sudden cardiac death. In the long run, however, we must also identify the subset of patients that currently undergo defibrillator implantation without deriving benefit. This is necessary, not only to reduce costs to society, but also to eliminate unnecessary device-related risks. Ultimately, future studies must examine the paradigm of risk stratification based only on late gadolinium enhancement and regardless of the left ventricular ejection fraction.
DISCLOSURES
Dr Nazarian serves as a scientific advisor for Biosense Webster, St. Jude Medical, and CardioSolv. He is a principal investigator for research grants from Biosense Webster and the National Institutes of Health.
